ALL Therapeutics

Pre-emptive versus prophylactic use of TKIs after allo-SCT in patients with Philadelphia chromosome-positive ALL

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion gene product have...

D-ALBA trial: How can we improve  dasatinib results in  newly diagnosed  Ph+ ALL?

During the EHA2021 Virtual Congress, the ALL Hub spoke with Sabina Chiaretti, Sapienza University of Rome, Rome, IT....

Updated results from the D-ALBA trial of dasatinib plus blinatumomab in newly diagnosed adult Ph+ ALL

The outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia...

What are the main advances in patient care that we are seeing with novel agents for leukemia?

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College...

What are the main advances in patient care that we are seeing with novel agents for leukemia? ASCO21

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Jorge Cortes, Augusta University,...

How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute...

The spleen as a site for residual disease in T-cell ALL

T-cell acute lymphoblastic leukemia (ALL) is highly aggressive and frequently spreads from the thymus to the bone marrow, liver, lymph nodes,...

Phase I results show venetoclax and navitoclax combination is tolerable and associated with responses in pediatric patients with R/R ALL and LL

The prognosis is poor for pediatric patients with...